The Oklahoma State Department of Health announced Monday that they will resume administration of the Johnson & Johnson vaccine in Oklahoma in alignment with the CDC and FDA. After carefully analyzing the data, the ACIP concluded the risk of the rare blood clotting reaction is minimal.
Learn more: http://ow.ly/mQen50ExS9h
